Name: Latest research reports of Eris Lifesciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Eris Lifesciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Eris Lifesciences Ltd.

NSE: ERIS | BSE: 540596 | ISIN: INE406M01024 | Industry: Pharmaceuticals
| Turnaround Potential

1763.6000 -16.30 (-0.92%)

NSE Sep 04, 2025 15:31 PM

60.74% Gain from 52W Low

Volume: 67,679

Eris Lifesciences Ltd.

22 May 2024

1763.60

-0.92%

Eris Lifesciences (BUY): Strong revenue growth; integration ongoing

Buy: Eris Lifesciences Ltd.

Target

BOB Capital Markets Ltd.

ERIS posted strong revenue performance in Q4 with a beat of 8%, but EBITDA came below BBG consensus due to higher opex and one-offs

Eris Lifesciences Ltd. has an average target of 1581.00 from 3 brokers.